Navigation Links
Dong-A PharmTech Co., Ltd. and Dr. Falk Pharma GmbH Announce Positive Data in Portal Hypertension With Udenafil
Date:6/13/2011

SEOUL, South Korea, June 13, 2011 /PRNewswire/ -- Dong-A PharmTech Co., Ltd. and Dr. Falk Pharma GmbH announced positive results from an initial safety and efficacy portal hypertension study in man using udenafil, its new long-active phosphodiesterase inhibitor. The data was presented by the principal investigator, Prof. Wolfgang Kreisel, Department of Gastroenterology, Hepatology, Endocrinology and Infectious Diseases, University of Freiburg, Freiburg, Germany.

In a 1-week open-label, multicenter phase 2 trial, 20 patients with portal hypertension (Child-Pugh A/B) that met the selection criteria were given a daily oral dose of one of four dose levels of udenafil. The primary efficacy endpoint was the change of hepatic venous pressure gradient (HVPG) from day 0 (pre dose) to day 6 post dose.  A total of 7 of 20 patients showed a response defined as a HVPG reduction of < 12 mmHG or by > 20% after one week of daily dosing.  In the high dose group, HVPG was lowered in 4 of the 5 patients by more than 10% after administration of study drug on day 0 or day 6.  No decrease of mean arterial blood pressure was seen in any of the four dose groups.  Standard liver biochemical tests did not change during the study and no adverse events were attributed to the study drug.

The results of this study show that the oral application of the new PDE-5 inhibitor udenafil lowers HVPG in an acute setting without any systemic cardiovascular side effects.  Effectiveness appears to be dose related.  Further study is contemplated using a placebo controlled design and a longer study duration.

About Dong-A PharmTech Co., Ltd.

Dong-A PharmTech is a late-stage pharmaceutical company incorporated in Korea, focused on the development and commercialization of udenafil worldwide excluding Korea.

About Dr. Falk Pharma GmbH .<
'/>"/>

SOURCE Dong-A PharmTech Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
2. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
3. Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... -- Levi & Korsinsky announces that a class action ... Court for the District of Nevada ... Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) securities between ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt . ... the Company violated federal securities laws by issuing false ...
(Date:8/28/2014)... 2014 According to a new ... (RFID) Market (Tags, Readers, Middleware, Printers and Cabinets) - ... 2014 - 2020" the global radiofrequency identification (RFID) market ... is expected to grow at a CAGR of 13.9% ... of USD 5.3 billion in 2020. Browse ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Multiforme Therapeutics in Asia-Pacific Markets to ... High Unmet Need in Newly Diagnosed ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... HERZELIYA, Israel, September 30 ... in an investment round led by 7 Health,Ventures. ... in the round as well. , ... optical guidance systems used,in Computer Tomography (CT), fluoroscopy ...
... Ill., Sept. 30 Life Spine announced today that ... 510(k) marketing approval to the SENTINEL Occipito-Cervico-Thoracic (OCT) System. ... and promotes fusion from the occiput to thoracic spine, ... procedures. Polyaxial screws are available in multiple diameters and ...
Cached Medicine Technology:
(Date:8/28/2014)... (PRWEB) August 29, 2014 ... brings pharmaceutical industry precision to the development and ... approval for its primary location in Sarasota County. ... decisively with a total commitment to attracting new ... to creating," says David Wright, President and CEO ...
(Date:8/28/2014)... Arizona (PRWEB) August 28, 2014 When ... and long-time friend of Mark Brnovich, was asked ... the Republican nomination for the Attorney General seat in ... He quickly gathered the support of Cardinal Hall of ... Arizona Cardinals Derek Kennard and Mark Walczak. Green, Kennard ...
(Date:8/28/2014)... 2014 New Energy Works Timberframe plans ... around the country to Log & Timber Home Shows ... The New Energy Works team will invite the shows’ ... and build expertise, project images, and their new 2015 ... Energy Works’ Mid-West Representative, will present “A fun-fill odyssey: ...
(Date:8/28/2014)... A 42-year-old investment banker arrives at the emergency ... tremor. He drinks alcohol every dayoften at business ... his health, he decided to quit drinking and ... to emergency. , It,s a common scenario in ... excessive alcohol consumption and develops withdrawal. , Withdrawal ...
(Date:8/28/2014)... On August 21, the Mesothelioma Applied ... featuring the organization’s audited financial information, as well as ... the report, in 2013, the Meso Foundation spent 86 ... on fundraising and administration. , “The Meso Foundation ... Foundation’s chief executive officer, Melinda Kotzian. , “As a ...
Breaking Medicine News(10 mins):Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 2Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 3Health News:Real tremors, or drug-seeking patient? New app can tell 2Health News:Real tremors, or drug-seeking patient? New app can tell 3Health News:Mesothelioma Applied Research Foundation’s Annual Report 2013 Release 2
... Calif., April 10, 2008 IPC,The Hospitalist Company, Inc. ... focused on the delivery of hospitalist medicine services,announced today ... 2008,ended March 31, 2008 on Wednesday, May 14, 2008, ... review the results will begin at 5:00 p.m. ET,(2:00 ...
... Partners With Asthma and Allergy Foundation of America To ... Combat Allergens in the Bedroom, ... with the Asthma and Allergy Foundation of America,(AAFA) to educate consumers ... spend one third of their lives: the bedroom., "Many people ...
... Brings Unique Opportunity to Emerging Hip-Hop ... Talent, ... & Gamble,s TAG brand announce the formation of a new,hip-hop record label, TAG ... act as president of the New York-based,venture. As president, Dupri will set the ...
... and OTTAWA, April 10 Natural,Nutrition, Inc. (OTC ... launch its new health and nutritional information portal,iNutrition.com, ... to consumers relating to a healthy lifestyle, nutrition ... as a trusted,healthcare and information resource for our ...
... One Consumer Request, PLANO, Texas, April 10 ... of Pinch of Salt, a,low-sodium version of some of ... chips, Fritos corn chips and Ruffles potato chips.,While Frito-Lay ... with,-- for instance Lay,s Classic potato chips contain 180 ...
... , CamelBak is pleased to announce that our ... by the end of April, 2008. First to,market in ... color, CamelBak will have an entirely BPA-free product line ... Better,Bottle(TM) with Bite Valve, the CamelBak Better Bottle(TM) with ...
Cached Medicine News:Health News:IPC The Hospitalist Company, Inc. to Report First Quarter 2008 Financial Results 2Health News:Leave Bedroom Allergens High and Dry This Spring! 2Health News:Leave Bedroom Allergens High and Dry This Spring! 3Health News:Jermaine Dupri and Island Def Jam Music Group Launch New Hip-Hop Label in Partnership with TAG Body Sprays 2Health News:Jermaine Dupri and Island Def Jam Music Group Launch New Hip-Hop Label in Partnership with TAG Body Sprays 3Health News:Natural Nutrition to Launch iNutrition.com 2Health News:Frito-Lay Launches Low Sodium Versions of its Top Selling Snack Chips 2
Assay for Anti-HTLV-I and Anti-HTLV-II...
... assays for the blood screening market. We have ... in contract funding from the National Heart, Lung, ... develop the Procleix WNV Assay. This assay was ... under an Investigational New Drug Application (IND) on ...
Test for Anti-HBc for use on the Abbott Prism...
... BenchMark XT® the only fully automated ... you need to expand your test ... your slide turnaround time. All with ... how to use the BenchMark XT® ...
Medicine Products: